Analytical performance of a new automated chemiluminescent magnetic immunoassays for soluble PD-1, PD-L1, and CTLA-4 in human plasma

Megumi Goto, Kenji Chamoto, Keiko Higuchi, Saya Yamashita, Kenta Noda, Takuya Iino, Masahiro Miura, Toshinari Yamasaki, Osamu Ogawa, Makoto Sonobe, Hiroshi Date, Junzo Hamanishi, Masaki Mandai, Yoshimasa Tanaka, Shunsuke Chikuma, Ryusuke Hatae, Manabu Muto, Sachiko Minamiguchi, Nagahiro Minato, Tasuku Honjo

Research output: Contribution to journalArticle

Abstract

Current clinically approved biomarkers for the PD-1 blockade cancer immunotherapy are based entirely on the properties of tumour cells. With increasing awareness of clinical responses, more precise biomarkers for the efficacy are required based on immune properties. In particular, expression levels of immune checkpoint-associated molecules such as PD-1, PD-L1, and CTLA-4 would be critical to evaluate the immune state of individuals. Although quantification of their soluble form leased from the membrane will provide quick evaluation of patients’ immune status, available methods such as enzyme-linked immunosorbent assays to measure these soluble factors have limitations in sensitivity and reproducibility for clinical use. To overcome these problems, we developed a rapid and sensitive immunoassay system based on chemiluminescent magnetic technology. The system is fully automated, providing high reproducibility. Application of this system to plasma of patients with several types of tumours demonstrated that soluble PD-1, PD-L1, and CTLA-4 levels were increased compared to those of healthy controls and varied among tumour types. The sensitivity and detection range were sufficient for evaluating plasma concentrations before and after the surgical ablation of cancers. Therefore, our newly developed system shows potential for accurate detection of soluble PD-1, PD-L1, and CTLA-4 levels in the clinical practice.

Original languageEnglish
Article number10144
JournalScientific reports
Volume9
Issue number1
DOIs
Publication statusPublished - 2019 Dec 1

Fingerprint

Immunoassay
Neoplasms
Biomarkers
Immunotherapy
Enzyme-Linked Immunosorbent Assay
Technology
Membranes

ASJC Scopus subject areas

  • General

Cite this

Analytical performance of a new automated chemiluminescent magnetic immunoassays for soluble PD-1, PD-L1, and CTLA-4 in human plasma. / Goto, Megumi; Chamoto, Kenji; Higuchi, Keiko; Yamashita, Saya; Noda, Kenta; Iino, Takuya; Miura, Masahiro; Yamasaki, Toshinari; Ogawa, Osamu; Sonobe, Makoto; Date, Hiroshi; Hamanishi, Junzo; Mandai, Masaki; Tanaka, Yoshimasa; Chikuma, Shunsuke; Hatae, Ryusuke; Muto, Manabu; Minamiguchi, Sachiko; Minato, Nagahiro; Honjo, Tasuku.

In: Scientific reports, Vol. 9, No. 1, 10144, 01.12.2019.

Research output: Contribution to journalArticle

Goto, M, Chamoto, K, Higuchi, K, Yamashita, S, Noda, K, Iino, T, Miura, M, Yamasaki, T, Ogawa, O, Sonobe, M, Date, H, Hamanishi, J, Mandai, M, Tanaka, Y, Chikuma, S, Hatae, R, Muto, M, Minamiguchi, S, Minato, N & Honjo, T 2019, 'Analytical performance of a new automated chemiluminescent magnetic immunoassays for soluble PD-1, PD-L1, and CTLA-4 in human plasma', Scientific reports, vol. 9, no. 1, 10144. https://doi.org/10.1038/s41598-019-46548-3
Goto, Megumi ; Chamoto, Kenji ; Higuchi, Keiko ; Yamashita, Saya ; Noda, Kenta ; Iino, Takuya ; Miura, Masahiro ; Yamasaki, Toshinari ; Ogawa, Osamu ; Sonobe, Makoto ; Date, Hiroshi ; Hamanishi, Junzo ; Mandai, Masaki ; Tanaka, Yoshimasa ; Chikuma, Shunsuke ; Hatae, Ryusuke ; Muto, Manabu ; Minamiguchi, Sachiko ; Minato, Nagahiro ; Honjo, Tasuku. / Analytical performance of a new automated chemiluminescent magnetic immunoassays for soluble PD-1, PD-L1, and CTLA-4 in human plasma. In: Scientific reports. 2019 ; Vol. 9, No. 1.
@article{1e33b8db3ba2429295bff18a8544f102,
title = "Analytical performance of a new automated chemiluminescent magnetic immunoassays for soluble PD-1, PD-L1, and CTLA-4 in human plasma",
abstract = "Current clinically approved biomarkers for the PD-1 blockade cancer immunotherapy are based entirely on the properties of tumour cells. With increasing awareness of clinical responses, more precise biomarkers for the efficacy are required based on immune properties. In particular, expression levels of immune checkpoint-associated molecules such as PD-1, PD-L1, and CTLA-4 would be critical to evaluate the immune state of individuals. Although quantification of their soluble form leased from the membrane will provide quick evaluation of patients’ immune status, available methods such as enzyme-linked immunosorbent assays to measure these soluble factors have limitations in sensitivity and reproducibility for clinical use. To overcome these problems, we developed a rapid and sensitive immunoassay system based on chemiluminescent magnetic technology. The system is fully automated, providing high reproducibility. Application of this system to plasma of patients with several types of tumours demonstrated that soluble PD-1, PD-L1, and CTLA-4 levels were increased compared to those of healthy controls and varied among tumour types. The sensitivity and detection range were sufficient for evaluating plasma concentrations before and after the surgical ablation of cancers. Therefore, our newly developed system shows potential for accurate detection of soluble PD-1, PD-L1, and CTLA-4 levels in the clinical practice.",
author = "Megumi Goto and Kenji Chamoto and Keiko Higuchi and Saya Yamashita and Kenta Noda and Takuya Iino and Masahiro Miura and Toshinari Yamasaki and Osamu Ogawa and Makoto Sonobe and Hiroshi Date and Junzo Hamanishi and Masaki Mandai and Yoshimasa Tanaka and Shunsuke Chikuma and Ryusuke Hatae and Manabu Muto and Sachiko Minamiguchi and Nagahiro Minato and Tasuku Honjo",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41598-019-46548-3",
language = "English",
volume = "9",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Analytical performance of a new automated chemiluminescent magnetic immunoassays for soluble PD-1, PD-L1, and CTLA-4 in human plasma

AU - Goto, Megumi

AU - Chamoto, Kenji

AU - Higuchi, Keiko

AU - Yamashita, Saya

AU - Noda, Kenta

AU - Iino, Takuya

AU - Miura, Masahiro

AU - Yamasaki, Toshinari

AU - Ogawa, Osamu

AU - Sonobe, Makoto

AU - Date, Hiroshi

AU - Hamanishi, Junzo

AU - Mandai, Masaki

AU - Tanaka, Yoshimasa

AU - Chikuma, Shunsuke

AU - Hatae, Ryusuke

AU - Muto, Manabu

AU - Minamiguchi, Sachiko

AU - Minato, Nagahiro

AU - Honjo, Tasuku

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Current clinically approved biomarkers for the PD-1 blockade cancer immunotherapy are based entirely on the properties of tumour cells. With increasing awareness of clinical responses, more precise biomarkers for the efficacy are required based on immune properties. In particular, expression levels of immune checkpoint-associated molecules such as PD-1, PD-L1, and CTLA-4 would be critical to evaluate the immune state of individuals. Although quantification of their soluble form leased from the membrane will provide quick evaluation of patients’ immune status, available methods such as enzyme-linked immunosorbent assays to measure these soluble factors have limitations in sensitivity and reproducibility for clinical use. To overcome these problems, we developed a rapid and sensitive immunoassay system based on chemiluminescent magnetic technology. The system is fully automated, providing high reproducibility. Application of this system to plasma of patients with several types of tumours demonstrated that soluble PD-1, PD-L1, and CTLA-4 levels were increased compared to those of healthy controls and varied among tumour types. The sensitivity and detection range were sufficient for evaluating plasma concentrations before and after the surgical ablation of cancers. Therefore, our newly developed system shows potential for accurate detection of soluble PD-1, PD-L1, and CTLA-4 levels in the clinical practice.

AB - Current clinically approved biomarkers for the PD-1 blockade cancer immunotherapy are based entirely on the properties of tumour cells. With increasing awareness of clinical responses, more precise biomarkers for the efficacy are required based on immune properties. In particular, expression levels of immune checkpoint-associated molecules such as PD-1, PD-L1, and CTLA-4 would be critical to evaluate the immune state of individuals. Although quantification of their soluble form leased from the membrane will provide quick evaluation of patients’ immune status, available methods such as enzyme-linked immunosorbent assays to measure these soluble factors have limitations in sensitivity and reproducibility for clinical use. To overcome these problems, we developed a rapid and sensitive immunoassay system based on chemiluminescent magnetic technology. The system is fully automated, providing high reproducibility. Application of this system to plasma of patients with several types of tumours demonstrated that soluble PD-1, PD-L1, and CTLA-4 levels were increased compared to those of healthy controls and varied among tumour types. The sensitivity and detection range were sufficient for evaluating plasma concentrations before and after the surgical ablation of cancers. Therefore, our newly developed system shows potential for accurate detection of soluble PD-1, PD-L1, and CTLA-4 levels in the clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=85068956302&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068956302&partnerID=8YFLogxK

U2 - 10.1038/s41598-019-46548-3

DO - 10.1038/s41598-019-46548-3

M3 - Article

C2 - 31300681

AN - SCOPUS:85068956302

VL - 9

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 10144

ER -